Oncologists backing of combo products supporting cytotoxic market
The popularity of combination therapies in the treatment of cancer is set to increase, which will help offset revenue losses in the cytotoxic therapies market due to blockbuster patent expiries, according to a new report by pharmaceutical experts GBI Research.
The new report suggests that oncological drug treatments are evolving to involve biologic medication, which, in combination with cytotoxic drugs, is fast-becoming the top pharmaceutical therapy.
The cytotoxic therapies market has eight major indications, namely breast cancer, cervical cancer, colorectal cancer, head and neck cancer, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer and prostate cancer. The average annual cost of therapy for cytotoxic therapies is estimated to decrease moderately over the coming years, to reach an approximate value of $7,660 by 2017. This is predicted to lead to a decrease in overall market value.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze